Efficacy of dendrimer‐mediated angiostatin and TIMP‐2 gene delivery on inhibition of tumor growth and angiogenesis: <i>In vitro</i> and <i>in vivo</i> studies

Vincent, Loı̈c; Varet, Julia; Pillé, Jean-Yves; Bompais, Heidi; Opolon, Paule; Maksimenko, Andrei; Malvy, Claude; Mirshahi, Manouchehr; Lű, He; Vannier, Jean‐Pierre; Soria, Claudine; Li, Hong

doi:10.1002/ijc.11105

Cited by 83 publications

(46 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has to be noted that numerous studies have investigated the efficacy/cytotoxicity/biodistribution profile of polyplexes by modifying molecular weight, ionic strength of the solution, zeta potential, degree of branching, and particle size (131,141). Chitosans (142), dendrimers (143), and poly(2-(dimethylamino)ethyl methacrylate) (144) are other cationic polymers that have been used for gene delivery purposes. For further details on delivery systems in cancer gene therapy, see the excellent review by El-Aneed (145).…”

Section: Nanotechnologies For the Delivery Of Nucleic Acidsmentioning

confidence: 99%

Nanotechnology: Intelligent Design to Treat Complex Disease

2006

View full text Add to dashboard Cite

The purpose of this expert review is to discuss the impact of nanotechnology in the treatment of the major health threats including cancer, infections, metabolic diseases, autoimmune diseases, and inflammations. Indeed, during the past 30 years, the explosive growth of nanotechnology has burst into challenging innovations in pharmacology, the main input being the ability to perform temporal and spatial site-specific delivery. This has led to some marketed compounds through the last decade. Although the introduction of nanotechnology obviously permitted to step over numerous milestones toward the development of the "magic bullet" proposed a century ago by the immunologist Paul Ehrlich, there are, however, unresolved delivery problems to be still addressed. These scientific and technological locks are discussed along this review together with an analysis of the current situation concerning the industrial development.

show abstract

Section: Nanotechnologies For the Delivery Of Nucleic Acidsmentioning

confidence: 99%

Nanotechnology: Intelligent Design to Treat Complex Disease

2006

View full text Add to dashboard Cite

show abstract

“…It has also been reported that TIMP-2 inhibits cell migration after TIMP-2 transfection of human microvascular endothelial cells (hMVECs; ref. 19). TIMP-2 has been reported to inhibit cell migration through inhibition of MMP activity, specifically MT1-MMP inhibition (19,20).…”

Section: Introductionmentioning

confidence: 99%

“…19). TIMP-2 has been reported to inhibit cell migration through inhibition of MMP activity, specifically MT1-MMP inhibition (19,20). However, many of these reports involve forced expression of TIMP-2 and, as a result, have not examined the kinetics of this effect.…”

Section: Introductionmentioning

confidence: 99%

Tissue Inhibitors of Metalloproteinase 2 Inhibits Endothelial Cell Migration through Increased Expression of RECK

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Their size, molecular weight, and surface functionalities can be easily controlled (10). The use of dendrimers in relation to angiogenesis has been restricted to applications such as MRI contrast agents of neovascularized areas and as carriers for antiangiogenic genes (11)(12)(13)(14). Most of these studies have focused on local administration of dendrimer-nucleic acid complexes (14,15).…”

mentioning

confidence: 99%

Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth

Al‐Jamal

Al-Jamal

Akerman

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

This study describes the previously unreported intrinsic capacity of poly-L-lysine (PLL) sixth generation (G(6)) dendrimer molecules to exhibit systemic antiangiogenic activity that could lead to solid tumor growth arrest. The PLL-dendrimer-inhibited tubule formation of SVEC4-10 murine endothelial cells and neovascularization in the chick embryo chick chorioallantoic membrane (CAM) assay. Intravenous administration of the PLL-dendrimer molecules into C57BL/6 mice inhibited vascularisation in Matrigel plugs implanted subcutaneously. Antiangiogenic activity was further evidenced using intravital microscopy of tumors grown within dorsal skinfold window chambers. Reduced vascularization of P22 rat sarcoma implanted in the dorsal window chamber of SCID mice was observed following tail vein administration (i.v.) of the PLL dendrimers. Also, the in vivo toxicological profile of the PLL-dendrimer molecules was shown to be safe at the dose regime studied. The antiangiogenic activity of the PLL dendrimer was further shown to be associated with significant suppression of B16F10 solid tumor volume and delayed tumor growth. Enhanced apoptosis/necrosis within tumors of PLL-dendrimer-treated animals only and reduction in the number of CD31 positive cells were observed in comparison to protamine treatment. This study suggests that PLL-dendrimer molecules can exhibit a systemic antiangiogenic activity that may be used for therapy of solid tumors, and in combination with their capacity to carry other therapeutic or diagnostic agents may potentially offer capabilities for the design of theranostic systems

show abstract

Efficacy of dendrimer‐mediated angiostatin and TIMP‐2 gene delivery on inhibition of tumor growth and angiogenesis: In vitro and in vivo studies

Cited by 83 publications

References 24 publications

Nanotechnology: Intelligent Design to Treat Complex Disease

Nanotechnology: Intelligent Design to Treat Complex Disease

Tissue Inhibitors of Metalloproteinase 2 Inhibits Endothelial Cell Migration through Increased Expression of RECK

Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth

Contact Info

Product

Resources

About